SMOFlipid

06/01/2012 - "Randomised trials are needed to study the efficacy of SMOFlipid in preventing PN liver disease."
01/01/2020 - "Use of SMOFlipid resulted in decreased development of IF-associated liver disease in patients with IF when assessed using biochemical tests."
05/01/2018 - "SMOFlipid has been associated with an improvement in biochemical parameters and delays progression of parenteral nutrition-associated liver disease (PNALD). "
01/01/2019 - "We describe the development of moderate EFA deficiency (EFAD) and slow weight gain in an infant with intestinal failure-associated liver disease managed with SMOFlipid reduction (1 g/kg/d). "
11/01/2020 - "Development of Parenteral Nutrition-Associated Liver Disease and Other Adverse Effects in Neonates Receiving SMOFlipid or Intralipid."

02/01/2022 - "We found that combining SMOFlipid with UDCA resulted in a significant reduction in cholestasis duration in both groups. "
02/01/2022 - "Infants in Group 2 who received SMOFlipid had cholestasis for a mean of 38.2 ± 28 days, and those who did not receive SMOFlipid had cholestasis for a mean of 117 ± 119 days (p=0.02). "
02/01/2022 - "Infants in Group 1 who received SMOFlipid had cholestasis for a mean of 67 ± 57 days, and those who did not receive SMOFlipid had cholestasis for a mean of 145 ± 102 days (p=0.04). "
05/01/2021 - "The incidence of PN-associated cholestasis was significantly lower in the SMOFlipid group than in the Lipovenoes group. "
01/01/2021 - "Sixteen patients (38%) with cholestasis had resolution with Smoflipid. "

04/01/2012 - "The SMOFlipid emulsion is a option for reversing hypotension in cases of intoxication by bupivacaine."
01/01/2016 - "The infusion of propofol Lipuro during prolonged periods, in addition to marked hypotension and hypoperfusion, also showed to have higher anti-oxidant activity and lower impairment of the mitochondrial function comparatively to the improved lipid formulation, SMOFlipid, using the rabbit as animal model. "

01/01/2021 - "Our objective was to characterize changes in FA profile, liver function, and growth in pediatric patients with intestinal failure (IF), following transition from SO or a fish-oil (FO) and SO combination to SMOFlipid. "
01/01/2021 - "Evaluation of SMOFlipid in Pediatric Intestinal-Failure Patients and Its Effects on Essential Fatty Acid Levels."
01/01/2020 - "Our objective was to compare outcomes in neonates with intestinal failure (IF) who received SMOFlipid against those receiving Intralipid. "
01/01/2017 - "Compared with Intralipid, SMOFlipid reduces the risk of progressive IFALD in children with intestinal failure. "
01/01/2019 - "We describe the development of moderate EFA deficiency (EFAD) and slow weight gain in an infant with intestinal failure-associated liver disease managed with SMOFlipid reduction (1 g/kg/d). "

01/01/2021 - "In an institutional review board-approved, multicenter retrospective review, the medical records of 328 patients who were born at a gestational age of ≤34 weeks, had a birth weight of 500 to 2,000 g, were admitted to one of 2 neonatal intensive care units (NICUs) within a large health system, and received at least 7 days of a parenteral nutrition containing either lipid emulsion product were reviewed: 151 (46%) had received SO-ILE and 177 (54%) had received SMOFlipid (Fresenius Kabi). "
10/01/2010 - "Sixty (30/30) premature neonates (age 3-7 days, gestational age ≤ 34 weeks, birth weights 1000-2500 g) received parenteral nutrition (PN) with either SMOFlipid 20% (study group) or a conventional lipid emulsion (Intralipid 20%, control group) for a minimum of 7 up to 14 days. "